PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmcpsycBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Psychiatry
 
BMC Psychiatry. 2011; 11: 86.
Published online May 17, 2011. doi:  10.1186/1471-244X-11-86
PMCID: PMC3123270
Aripiprazole Augmentation in the Treatment of Military-Related PTSD with Major Depression: a retrospective chart review
J Don Richardson,corresponding author1,2,3 Deniz Fikretoglu,4,5 Aihua Liu,6 and Diane McIntosh7
1Operational Stress Injury Clinic, St. Joseph's Health Care London - Parkwood Hospital, London, Ontario, Canada
2National Centre for Operational Stress Injuries, Veterans Affairs Canada, Montreal, Quebec, Canada
3Department of Psychiatry, Schulich School of Medicine and Dentistry, University of Western Ontario, Canada
4Defense Research and Development Canada, Toronto, Canada
5Douglas Mental Health University Institute, McGill University, Montreal, Quebec, Canada
6Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada
7Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada
corresponding authorCorresponding author.
J Don Richardson: Don.Richardson/at/sjhc.london.on.ca; Deniz Fikretoglu: DENIZ.FIKRETOGLU/at/forces.gc.ca; Aihua Liu: liuaihua2002/at/yahoo.com; Diane McIntosh: drdianemcintosh/at/gmail.com
Received January 12, 2011; Accepted May 17, 2011.
Abstract
Background
In this chart review, we attempted to evaluate the benefits of adding aripiprazole in veterans with military-related PTSD and comorbid depression, who had been minimally or partially responsive to their existing medications.
Methods
A retrospective chart review of patients who received an open-label, flexible-dose, 12- week course of adjunctive aripiprazole was conducted in 27 military veterans meeting DSM-IV criteria for PTSD and comorbid major depression. Concomitant psychiatric medications continued unchanged, except for other antipsychotics which were discontinued prior to initiating aripiprazole. The primary outcome variable was a change from baseline in the PTSD checklist-military version (PCL-M) and the Beck Depression Inventory (BDI-II).
Results
PTSD severity (Total PCL scores) decreased from 56.11 at baseline to 46.85 at 12-weeks (p < 0.0001 from Wilcoxon signed rank test) and the depression severity decreased from 30.44 at baseline to 20.67 at 12-weeks (p < 0.0001 from Wilcoxon signed rank test). Thirty seven percent (10/27) were considered responders, as defined by a decrease in total PCL scores of at least 20 percent and 19% (5/27) were considered as responders as defined by a decrease in total BDI score of at least 50%.
Conclusions
The addition of aripiprazole contributed to a reduction in both PTSD and depression symptomatology in a population that has traditionally demonstrated poor pharmacological response. Further investigations, including double-blind, placebo-controlled studies, are essential to confirm and further demonstrate the benefit of aripiprazole augmentation in the treatment of military related PTSD.
Articles from BMC Psychiatry are provided here courtesy of
BioMed Central